{"generic":"Colestilan","drugs":["Colestilan"],"mono":{"0":{"id":"jxxms0","title":"Generic Names","mono":"Colestilan"},"1":{"id":"jxxms1","title":"Dosing and Indications","sub":[{"id":"jxxms1b4","title":"Adult Dosing","mono":"<ul><li>colestilan has central marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li><b>Chronic kidney disease stage 5, in patients receiving hemodialysis or peritoneal dialysis - Hyperphosphatemia:<\/b> initial, 6 to 9 g\/day ORALLY in 2 to 3 divided doses; may increase dose by 3 g\/day (1 g 3 times daily) in 2 to 3 weekly intervals based on serum phosphorus concentrations; MAX 15 g\/day (5 g 3 times daily) (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"jxxms1b5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients younger than 18 years "},{"id":"jxxms1b6","title":"Dose Adjustments","mono":"<ul><li>renal impairment, not studied in pre-dialysis patients<\/li><li><b>hepatic impairment, severe:<\/b> use not recommended<\/li><\/ul>"},{"id":"jxxms1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Chronic kidney disease stage 5, in patients receiving hemodialysis or peritoneal dialysis - Hyperphosphatemia<br\/>"}]},"3":{"id":"jxxms3","title":"Contraindications\/Warnings","sub":[{"id":"jxxms3b9","title":"Contraindications","mono":"<ul><li>bowel obstruction<\/li><li>hypersensitivity to colestilan or any component of the product<\/li><\/ul>"},{"id":"jxxms3b10","title":"Precautions","mono":"<ul><li>albumin, serum, less than 30 g\/L; not recommended<\/li><li>biliary obstruction; not recommended<\/li><li>conditions that predispose to gastrointestinal (GI) hemorrhage (eg, recent history of GI hemorrhage, gastritis, diverticulosis, colitis, hemorrhoids)<\/li><li>dysphagia or swallowing disorders; not recommended<\/li><li>folate deficiency due to impaired intestinal absorption may occur with long-term treatment; monitoring recommended<\/li><li>gastrointestinal (GI) disorders, severe (eg, chronic or severe constipation, intestinal stenosis, intestinal diverticulum, sigmoid colitis, GI ulcers, recent major GI surgery); not recommended<\/li><li>hepatic impairment, severe; not recommended<\/li><li>hypocalcemia or hypercalcemia may occur; monitoring recommended<\/li><li>hypothyroidism; monitoring recommended when using concomitant levothyroxine<\/li><li>intestinal obstruction and ileus\/subileus has been reported; may be preceded by constipation; monitoring of constipated patients recommended; consider alternative treatment if severe constipation or other severe gastrointestinal symptoms develop<\/li><li>ion balance, systemic changes (chloride increase and bicarbonate decrease) may occur<\/li><li>malabsorption, concomitant use of coumarin anticoagulants, or other predisposing conditions for vitamin K or fat-soluble vitamin deficiencies; monitoring recommended<\/li><li>peritonitis, recent history of in peritoneal dialysis patients; not recommended<\/li><li>seizure disorders; not recommended<\/li><\/ul>"},{"id":"jxxms3b11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"jxxms3b12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"5":{"id":"jxxms5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypocalcemia (1% to less than 10%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal discomfort (1% to less than 10%), Abdominal distension (1% to less than 10%), Abdominal pain (1% to less than 10%), Constipation (1% to less than 10%), Decrease in appetite (1% to less than 10%), Diarrhea (1% to less than 10%), Flatulence (1% to less than 10%), Gastritis (1% to less than 10%), Indigestion (1% to less than 10%), Nausea (1% to less than 10%), Vomiting (1% to less than 10%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Coronary arteriosclerosis (0.01% to less than 0.1%)<\/li><li><b>Gastrointestinal:<\/b>Bowel obstruction (0.01% to less than 0.1%), Dysphagia (0.1% to less than 1%), Esophagitis (0.1% to less than 1%), Gastroenteritis (0.1% to less than 1%), Gastrointestinal hemorrhage (0.1% to less than 1%)<\/li><\/ul>"},"6":{"id":"jxxms6","title":"Drug Name Info","sub":{"2":{"id":"jxxms6b19","title":"Class","mono":"Bile Acid Sequestrant<br\/>"},"3":{"id":"jxxms6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"jxxms9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>(tablets) swallow whole<\/li><li>(granules) take whole as 1 dose from sachet<\/li><li>administer with or immediately after meals with enough water to ensure swallowing<\/li><li>patients should be encouraged to adhere to a low-phosphate diet<\/li><\/ul>"}}}